Skip to Content
Go to HCA Healthcare
HCA Healthcare Sarah Cannon Cancer Network

Transplant and cellular therapy

The Sarah Cannon Transplant and Cellular Therapy Network consists of 13 programs with 10 locations in the U.S. and three in the UK that provide care to patients with complex blood cancers such as leukemia, patients receiving blood and marrow transplant and cellular therapy, and patients receiving gene therapy for blood diseases.

One comprehensive approach to blood cancer care.

 

With 1,200 colleagues across the HCA Healthcare ecosystem, together our team of experts is leading care and innovation for patients throughout every step of their journey.

Research

We provide clinical trials in partnership with Sarah Cannon Research Institute. Our network enrolls more than 200 patients on clinical trials each year.

Experience

Annually, we care for more than 1,000 acute leukemia patients and perform more than 1,500 blood and marrow transplants, cellular therapies, and gene therapies for blood diseases.

Innovation

We lead care innovation by leveraging data and technology. As example, we use remote patient monitoring to provide outpatient care to CART cell therapy recipients.

Quality

With an emphasis on quality of care the network maintains 9 FACT/JACIE accredited programs with all programs meeting national benchmarks for survival outcomes.


The experience of our centers is reflected in the 16,000+ transplants performed since inception. With more than 1,500 transplant and cellular therapy procedures performed across 13 programs annually, Sarah Cannon Transplant & Cellular Therapy Network is the largest provider of blood and marrow transplants, cellular therapies, and gene therapies for blood diseases in the United States.

Our pursuit of excellent patient care in collaboration with Sarah Cannon Research Institute’s (SCRI) dedication to advancing oncology research provides exceptional cancer care for patients across the United States.